| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Pulsatilla saponin D (SB365), a naturally-occurring chemical isolated from the root of Pulsatilla koreana, has been used as a traditional medicine for the treatment of several diseases. SB365 strongly suppressed the growth and proliferation of colon cancer cells and induced their apoptosis. Also, SB365 showed anti-angiogenic activity by decreasing the expression of HIF-1α and VEGF. These results were confirmed by an in vivo study showing that SB365 significantly inhibited tumor growth by the induction of apoptosis and inhibition of angiogenesis with stronger anticancer activity than 5-FU. When further examined for its anticancer mechanism, SB365 effectively suppressed the AKT/mTOR pathway both in vitro and in vivo. Taken together, our study demonstrated that SB365 inhibits the AKT/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis. Therefore, SB365 is a good candidate as a natural product for use in the treatment of colon cancer.
| ln Vitro |
Apoptotic effects are demonstrated by pulsatilla saponin D (SB365), which is also associated with elevated cleaved caspase-3 and poly(ADP-ribose) polymerase evidence [1]. In gastric cancer cells, pulsatilla saponin D (SB365) significantly suppresses c-Met expression [1]. The growth and proliferation of five human pancreatic cancer cell lines (MIAPaCa-2, BXPC-3, PANC-1, AsPC-1, and HPAC) are significantly inhibited by pulsatilla saponin D (SB365) [2]. The anti-angiogenic effect of Pulsatilla saponin D (SB365) is demonstrated by its ability to decrease the expression of VEGF and HIF-1α. In NSCLC cancer cells, pulsatilla saponin D (0.3 ng/mL to 10 μg/mL) shows anti-tumor action [4].
|
|---|---|
| ln Vivo |
In the Lewis lung cancer model, pulsatilla saponin D (6.4 mg/kg) demonstrates anticancer efficacy [4].
|
| Cell Assay |
Cytotoxicity assay[4]
Cell Types: A-549, SKMEL-2, MCF-7 and Lewis lung cancer (LLC) cells. Tested Concentrations: 0.3 ng/mL to 10 μg/mL. Incubation Duration: 72 hrs (hours). Experimental Results: The ED50 value of A-549 cells was 6.3 μg/mL. |
| Animal Protocol |
Animal/Disease Models: 2x2x2 mm3 tumor fragments from Lewis lung cancer (LLC) were transplanted subcutaneously (sc) (sc) into the auxiliary area of BDF1 mice [4].
Doses: 6.4 mg/kg. Route of Administration: intraperitoneal (ip) injection on days 1 to 7 and 9 to 14. Experimental Results: Such potent antitumor effect on solid tumors (IR, 82%), higher than that of doxorubicin (IR, 64%). |
| References |
|
| Additional Infomation |
Pulsatilla saponin D is a triterpenoid. It has a role as a metabolite.
Pulsatilla saponin D has been reported in Serjania salzmanniana, Anemone coronaria, and Hedera colchica with data available. |
| Molecular Formula |
C47H76O17
|
|---|---|
| Molecular Weight |
913.0962
|
| Exact Mass |
912.508
|
| CAS # |
68027-15-6
|
| PubChem CID |
11650910
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
997.6±65.0 °C at 760 mmHg
|
| Flash Point |
285.4±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.619
|
| LogP |
5.77
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
64
|
| Complexity |
1750
|
| Defined Atom Stereocenter Count |
23
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@H]3CC[C@]4([C@H]([C@]3(C)CO)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)O
|
| InChi Key |
SOLICHUQXFAOEP-YDIXZRNLSA-N
|
| InChi Code |
InChI=1S/C47H76O17/c1-22-30(50)33(53)35(55)38(60-22)64-37-32(52)26(62-39-36(56)34(54)31(51)25(19-48)61-39)20-59-40(37)63-29-11-12-43(4)27(44(29,5)21-49)10-13-46(7)28(43)9-8-23-24-18-42(2,3)14-16-47(24,41(57)58)17-15-45(23,46)6/h8,22,24-40,48-56H,9-21H2,1-7H3,(H,57,58)/t22-,24-,25+,26-,27+,28+,29-,30-,31+,32-,33+,34-,35+,36+,37+,38-,39-,40-,43-,44-,45+,46+,47-/m0/s1
|
| Chemical Name |
(4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-9-(hydroxymethyl)-10-[(2S,3R,4S,5S)-4-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| Synonyms |
SB365; SB-365; SB 365; Hederacolchiside A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 39 mg/mL (~42.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0952 mL | 5.4759 mL | 10.9517 mL | |
| 5 mM | 0.2190 mL | 1.0952 mL | 2.1903 mL | |
| 10 mM | 0.1095 mL | 0.5476 mL | 1.0952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA